Moderna Inc. is in discussions with large drugmakers and financial firms to get funding for some late-stage vaccine trials as ...

After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...

The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it.

The Trump administration has canceled $766 million awarded to Moderna to develop a vaccine against potential pandemic ...

The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...